FDA Advisory Committee Information Collection: What It Means for Your QMS

Q: Who should submit comments to this FDA Federal Register notice?

Any organization that participates in or is affected by FDA advisory committee proceedings should consider submitting a comment. This includes medical device manufacturers with PMA-approved or PMA-pending Class III devices, clinical researchers, patient advocacy organizations, and trade associations such as AdvaMed or MDMA.

Last updated: 2026-04-08

On March 23, 2026, the FDA published a Federal Register notice (Docket No. 2026-05623) announcing a proposed extension of an existing information collection activity related to FDA advisory committees. Under the Paperwork Reduction Act of 1995 (PRA), the Agency is required to publish such notices and allow a 60-day public comment window before moving forward.

Most medical device manufacturers read notices like this one and immediately file them under "not my problem." That is a mistake. Advisory committee processes shape the evidentiary standards the FDA uses to evaluate your devices, and changes to how that information is collected — or how the public participates — ripple downstream into your Quality Management System (QMS), your 510(k) and PMA submissions, and even your post-market surveillance obligations. In this article, I'll break down exactly what this notice means, why it matters to your organization, and what you should consider doing about it before the comment window closes.

What Is an FDA Information Collection Activity?

Under the Paperwork Reduction Act of 1995 (44 U.S.C. § 3501 et seq.), every federal agency — including the FDA — must receive Office of Management and Budget (OMB) approval before collecting information from the public. "Information collection" is broadly defined and includes surveys, reporting requirements, recordkeeping mandates, and third-party disclosures.

The PRA process is designed to reduce unnecessary regulatory burden on businesses and individuals. For medical device companies, this matters because FDA information collections directly govern:

What data you must submit in premarket applications
How advisory committees evaluate your clinical evidence
What public participation looks like in device review panels
The administrative burden your regulatory affairs team carries

When the FDA seeks to extend or modify one of these collections, it is legally required to publish in the Federal Register, invite 60 days of public comment, and then reconcile those comments before submitting its request to OMB. The March 23, 2026 notice initiates exactly that process for its advisory committee information collection.

Understanding FDA Advisory Committees and Their Role in Device Regulation

FDA advisory committees are panels of independent experts — typically physicians, scientists, statisticians, and patient advocates — convened to advise the FDA on complex scientific and regulatory questions. For medical device manufacturers, the most relevant panels fall under the Medical Devices Advisory Committee, which includes over 18 specialized panels covering areas from cardiovascular devices to in vitro diagnostics.

Advisory committee recommendations are not legally binding, but in practice they carry enormous weight. According to FDA's own published data, the Agency follows advisory committee recommendations approximately 78% of the time. For high-risk Class III devices requiring a PMA, a negative panel vote can effectively halt a product's path to market.

The information collection covered by this Federal Register notice governs how the FDA solicits, gathers, and manages information in connection with these committee meetings — including nomination processes, conflict-of-interest disclosures, public docket submissions, and meeting materials provided to panelists.

What Specifically Is Being Proposed in the March 2026 Notice?

The March 23, 2026 Federal Register notice covers a proposed extension of an existing information collection — meaning the FDA is not introducing a new collection, but rather continuing an established one with a fresh OMB authorization period (typically three years).

Key elements of the collection likely include:

Collection Element	Relevant Party	Primary Regulatory Basis
Advisory committee member nominations	Manufacturers, clinicians, patient groups	21 CFR Part 14
Conflict-of-interest disclosures	Proposed committee members	18 U.S.C. § 208; 21 CFR 14.80
Public docket submissions (written comments)	Any member of the public, including manufacturers	21 CFR 14.29
Meeting agenda and briefing documents	FDA staff and sponsors (manufacturers)	21 CFR 14.22
Oral presentations at open meetings	Sponsors and public participants	21 CFR 14.25
Post-meeting follow-up data requests	Device sponsors	21 CFR 14.171

For manufacturers preparing for a panel meeting, each row in that table represents a potential compliance touchpoint in your regulatory submission process. Changes to how the FDA collects or processes any of these items can affect your timeline, your resource allocation, and the quality of information the panel ultimately reviews about your device.

Why the "Proposed Extension" Label Doesn't Mean "Business as Usual"

One of the most common misreadings I see from regulatory affairs teams is treating a PRA extension notice as a rubber-stamp formality. It is not. Here's why:

1. Extensions Can Include Burden Estimate Revisions

When the FDA submits its renewal to OMB, it includes an updated estimate of the annual burden hours the collection imposes on respondents. If the FDA has underestimated that burden — and many device manufacturers would argue it chronically does — now is your opportunity to provide documented evidence to the contrary.

The FDA's information collection burden estimates directly influence OMB's assessment of regulatory cost-benefit ratios. If actual burden is materially higher than estimated, and manufacturers fail to say so during the comment window, those underestimates get locked in for another three-year authorization cycle.

2. The 60-Day Window Is Genuinely Finite

The comment period opened March 23, 2026. That means the window closes on or around May 22, 2026. After that, the FDA will compile and respond to comments before submitting to OMB. If your organization wants to influence the collection's scope, burden estimates, or procedural mechanics, you have a defined — and rapidly closing — window to act.

3. Advisory Committee Procedural Standards Are Evolving

In recent years, the FDA has been under increasing pressure from Congress, patient advocates, and industry to improve transparency and consistency in advisory committee processes. The way information is collected and disseminated in these proceedings is actively evolving. This PRA notice is one mechanism through which those procedural changes get formalized.

Implications for Your ISO 13485-Compliant QMS

You might be wondering: what does a Federal Register PRA notice have to do with my ISO 13485 Quality Management System? More than you might think.

ISO 13485:2016 clause 4.1.1 requires organizations to document the scope of their QMS and address any applicable regulatory requirements. The FDA's advisory committee information collection processes are part of the broader regulatory environment your QMS must account for — particularly if you are pursuing or maintaining a PMA-approved Class III device.

Here are three specific QMS touchpoints to examine:

Regulatory Intelligence (ISO 13485:2016 Clause 4.2.3 / 21 CFR 820.30)

Your organization should have a documented process for monitoring and incorporating changes to applicable regulatory requirements. PRA notices in the Federal Register represent exactly this kind of signal. If your regulatory intelligence process doesn't include Federal Register monitoring for information collection activities that affect your submission categories, you have a gap worth closing.

Document Control for Advisory Committee Submissions (ISO 13485:2016 Clause 4.2.4)

Any briefing documents, dossiers, or clinical summaries submitted to an FDA advisory committee panel should be controlled documents within your QMS. Changes to FDA's information collection requirements for these materials — even subtle ones like revised formatting guidance or new submission portal requirements — need to be reflected in your controlled document templates. Review ISO 13485:2016 clause 4.2.4 to ensure your document control procedure explicitly addresses regulatory submission packages.

Post-Market Surveillance and Feedback Loops (ISO 13485:2016 Clause 8.2.1)

Advisory committee meetings are increasingly a venue where real-world post-market data is scrutinized. Panels reviewing PMA supplements or safety-related label changes will often request post-market surveillance data directly from the sponsor. If your PMS system (required under ISO 13485:2016 clause 8.2.1 and EU MDR Article 83) is not generating data in formats compatible with FDA advisory committee expectations, you may face last-minute scrambles when a panel meeting is scheduled.

What Should Medical Device Companies Do Right Now?

Having helped more than 200 medical device clients navigate FDA regulatory processes at Certify Consulting, I can tell you that companies who engage proactively with PRA notices — even the seemingly routine ones — consistently position themselves better in front of advisory committees than those who don't. Here is a practical action checklist:

Step 1: Assess Your Exposure

Determine whether your current device portfolio includes any products that have been, are currently, or are likely to be reviewed by an FDA advisory committee. If the answer is yes, the March 2026 information collection extension is directly relevant to your regulatory affairs operations.

Step 2: Review the Existing Burden Estimates

The Federal Register notice will include the FDA's estimated annual burden (in hours and respondent counts) for each element of the collection. Compare those estimates against your organization's actual experience preparing for and participating in advisory committee meetings. If there is a material discrepancy, document it with specifics: hours spent, staff involved, and the nature of the tasks.

Step 3: Draft and Submit a Comment

This is the step most companies skip — and it's the most valuable one. Submitting a comment through regulations.gov takes less time than most regulatory teams assume, and it creates a documented record of your organization's position. Effective comments:

Are specific, not generic ("Our organization spent approximately 312 staff hours preparing our most recent advisory committee briefing document" is far more useful than "The burden is too high")
Reference the specific collection elements under discussion
Propose concrete, actionable adjustments (e.g., revised burden hour estimates, clarification of submission format requirements)
Are signed by a named regulatory professional with relevant credentials

Step 4: Update Your QMS Regulatory Register

Regardless of whether you submit a comment, document this Federal Register notice in your regulatory requirements register (required under ISO 13485:2016 clause 4.1.1). Note the docket number (2026-05623), the comment deadline, and the current OMB control number for this collection. Assign a responsible owner to monitor the OMB's eventual authorization decision.

Step 5: Reassess Your Advisory Committee Readiness

Use this notice as a trigger to audit your organization's overall advisory committee preparedness. Key questions to address:

Do we have a documented SOP for advisory committee participation?
Are our clinical data packages formatted in accordance with current FDA guidance?
Have we mapped our post-market surveillance outputs to likely advisory committee data requests?
Do our conflict-of-interest disclosure processes align with 21 CFR Part 14 requirements?

A Broader Pattern: FDA's Increasing Use of Information Collection Modernization

This notice does not exist in a vacuum. Over the past several years, the FDA has been systematically modernizing its information collection infrastructure, driven in part by the FDA Safety and Innovation Act (FDASIA), the 21st Century Cures Act, and more recently, the FDA's own Digital Transformation Initiative.

Manufacturers who treat each PRA notice as an isolated administrative event are missing the cumulative signal: the FDA is building a more data-intensive, digitally integrated regulatory process. Advisory committee proceedings are increasingly data-rich — incorporating real-world evidence, patient-reported outcomes, and digital health data alongside traditional clinical trial data. Each PRA extension or modification is a step in that direction.

The companies best positioned to succeed in this environment are those with QMS architectures that treat regulatory intelligence as a continuous, systematic function — not a reactive one.

How Certify Consulting Can Help

At Certify Consulting, we have supported more than 200 medical device organizations — from startup Class II manufacturers to multinational PMA holders — in navigating exactly this kind of regulatory complexity. Our approach integrates ISO 13485 QMS compliance with FDA regulatory strategy, so that your quality system and your regulatory submissions are always aligned.

If you are uncertain about your organization's advisory committee readiness, or if you want support drafting a substantive comment to the March 2026 PRA notice, visit certify.consulting to schedule a consultation with our team.

For more foundational information on building an ISO 13485-compliant QMS that accounts for FDA requirements, see our guide on ISO 13485 regulatory requirements integration and our overview of FDA QSR and ISO 13485 alignment.

Key Takeaways

The FDA's March 23, 2026 Federal Register notice opens a 60-day comment window (closing ~May 22, 2026) on an information collection extension covering FDA advisory committee processes.
Advisory committees influence approximately 78% of FDA final decisions on complex device applications, making these proceedings highly material to PMA and Class III manufacturers.
ISO 13485:2016 clauses 4.1.1, 4.2.3, 4.2.4, and 8.2.1 all have direct relevance to how your QMS should account for advisory committee information collection requirements.
Companies that submit substantive, data-backed comments during the PRA comment window can directly influence the burden estimates and procedural standards locked in for the next three-year OMB authorization cycle.
This notice is part of a broader FDA trend toward more data-intensive, digitally integrated advisory committee proceedings — a trend your QMS regulatory intelligence function should be actively tracking.

FAQ

What is the FDA's proposed information collection activity published March 23, 2026?

The FDA published a Federal Register notice (Docket 2026-05623) proposing an extension of its existing information collection activities related to FDA advisory committees. Under the Paperwork Reduction Act of 1995, this notice opens a 60-day public comment window before the FDA submits the collection for OMB reauthorization.

Who should submit comments to this FDA Federal Register notice?

Any organization that participates in — or is affected by — FDA advisory committee proceedings should consider submitting a comment. This includes medical device manufacturers with PMA-approved or PMA-pending Class III devices, clinical researchers, patient advocacy organizations, and trade associations such as AdvaMed or MDMA.

How do FDA advisory committee processes relate to ISO 13485 compliance?

ISO 13485:2016 requires organizations to identify and account for applicable regulatory requirements within their QMS (clause 4.1.1). FDA advisory committee information collection requirements are part of that regulatory environment, particularly for manufacturers of high-risk devices subject to panel review. Relevant QMS processes include regulatory intelligence (clause 4.2.3), document control for submission packages (clause 4.2.4), and post-market surveillance data outputs (clause 8.2.1).

What happens if no comments are submitted during the 60-day window?

If the FDA receives no substantive comments, it will proceed with its existing burden estimates and collection parameters and submit the renewal to OMB largely unchanged. Those estimates and parameters then govern the collection for the next three-year authorization period. Organizations that fail to comment forfeit their ability to formally influence those standards until the next renewal cycle.

How often does the FDA follow advisory committee recommendations?

According to FDA's own published data, the Agency follows advisory committee recommendations approximately 78% of the time. For Class III medical devices requiring premarket approval, advisory committee votes are among the most consequential regulatory events a manufacturer will face.

Last updated: 2026-04-08

Jared Clark is Principal Consultant at Certify Consulting. He holds a JD, MBA, PMP, CMQ-OE, CPGP, CFSQA, and RAC, and has served more than 200 medical device clients with a 100% first-time audit pass rate. Visit certify.consulting to learn more.